Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6112601 | 0.87 | ADORA2A (0.73) | ADORA2AADORA2B | |
| SCHEMBL14088988 | 0.85 | AHCY (0.70) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL14075801 | 0.85 | AHCY (0.70) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL18172261 | 0.83 | ADORA3 (0.72) | ADORA3ADORA2AADORA2B | |
| SCHEMBL8619750 | 0.80 | ADORA2A (0.60) | ADORA2AADORA2B | |
| SCHEMBL8619744 | 0.80 | ADORA2A (0.60) | ADORA2AADORA2B | |
| SCHEMBL2776512 | 0.79 | ADORA2A (0.75) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4160652 | 0.78 | ADORA3 (0.73) | ADORA3ADORA2AADORA2B | |
| SCHEMBL4452559 | 0.77 | ADORA3 (0.77) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL19843948 | 0.77 | ADORA3 (0.77) | ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807685-B2 | Therapeutic compounds | CBT DEVELOPMENT LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-7807685-B2 | Therapeutic compounds | CBT DEVELOPMENT LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-7807685-B2 | Therapeutic compounds | CBT DEVELOPMENT LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| EP-2081946-A2 | ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN | Biovitrum AB (publ) (SE) | 2009-07-29 | — | — | EP | disclosed |
| US-20080076776-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076776-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076776-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-03-27 | — | — | US | disclosed |
| WO-2008000745-A2 | ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN | BIOVITRUM AB (PUBL) (SE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076776-A1 | Therapeutic compounds | FPR3, OGFR, OPRK1 | ADORA3 370/4885ADORA2A 1448/4885ADORA2B 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.